Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Oct
11
2022
California Passes New Law Requiring Physicians and their Employers to Notify Patients about the Open Payments Database Mintz
Nov
10
2022
Smoked Out: How Those In The Cannabis Industry May Finally Gain Bankruptcy Protection Mintz
Jan
3
2023
Cosmetic Regulatory Reform Finally Becomes Law Mintz
Jun
30
2015
FDA Provides 11th Hour Delay of Product Tracing Requirements for Pharmacies Mintz
Sep
30
2019
Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology Mintz
Sep
1
2015
FDA’s New Four-Letter Guidance on Biosimilars Mintz
Mar
20
2023
FDA Modernizes Mammography Regulations, Provides Facilities with Eighteen-Month Compliance Deadline Mintz
Sep
17
2015
Senators to Receive Update on Biosimilar Implementation from CDER’s Woodcock Mintz
Nov
7
2019
FDA Issues Drug Shortage Report Identifying Root Causes and Potential Solutions Mintz
Nov
23
2015
Congressional Hearing Examines Competition in PBM Industry Mintz
Dec
17
2019
New Revised USMCA Trade Deal Affects Intellectual Property Rights, But Not Exclusivity Period For Biologics Mintz
Mar
2
2016
Kyle Bass’ Another Three IPRs: Targeting Anacor Mintz
Jun
7
2016
Pharmacy Summit White Paper Highlights Drug Development Process Mintz
Jul
18
2016
House Passes GE Labeling Bill; Obama Expected to Sign Mintz
Aug
31
2016
6-Month Notice from a Biosimilar Sponsor Always Required — Says Federal Circuit Mintz
Jan
12
2017
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress Mintz
Jan
17
2017
FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns” Mintz
Aug
20
2020
With Release of New Guidance, FDA Signals It’s Serious About Enforcing Clinical Trial Data Requirements Mintz
Apr
9
2024
PBM Policy and Legislative Update — Winter 2024 Mintz
Mar
16
2017
21st Century Cures Act Developments: FDA Proposes Class II Device Exemptions Mintz
Jan
18
2021
340B Administrative Dispute Resolution Goes Live Amid a Flurry of 340B Litigation Mintz
Jun
29
2017
Massachusetts House and Senate Tackle Marijuana Mintz
Apr
8
2021
FDA’s Biologics Inspections in the (Negative) Limelight: Will Congress or Executive Leadership Take Action? Mintz
Aug
9
2017
Reading the Tea Leaves: Sales of Macadamia Nut Could Be Going Up! Mintz
Oct
10
2017
OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress Mintz
Mar
4
2012
Energy & Clean Tech Connections - Recent Washington D.C. Updates Mintz
May
21
2012
Energy and Environmental Law Update - May 20, 2012 Mintz
Aug
20
2012
Energy and Environment Law Update August 20, 2012 Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins